Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
December 8th, 2023
2.1K views
This protocol details the enrichment of native mycobacterial extracellular vesicles (mEVs) from axenic cultures of Mycobacterium smegmatis (Msm) and how mCherry (a red fluorescent reporter)-containing recombinant MsmEVs can be designed and enriched. Lastly, it verifies the novel approach with the enrichment of MsmEVs containing the EsxA protein of Mycobacterium tuberculosis.
Overview
This protocol details the enrichment of native mycobacterial extracellular vesicles (mEVs) from axenic cultures of Mycobacterium smegmatis (Msm). It also describes the design and enrichment of mCherry-containing recombinant MsmEVs and verifies this novel approach with the enrichment of MsmEVs containing the EsxA protein of Mycobacterium tuberculosis.
Key Study Components
Area of Science
- Microbiology
- Vaccine Development
- Extracellular Vesicles
Background
- Mycobacterial extracellular vesicles (EVs) play a crucial role in intercellular communication.
- Different series of EVs are generated from various locations on the bacterial surface.
- Affinity-based approaches can only enrich a subset of EVs due to the lack of conserved markers.
- This study presents a method to capture all generated mycobacterial EVs.
Purpose of Study
- To enrich native mycobacterial EVs for content analysis.
- To design and generate recombinant EVs for potential vaccine candidates.
- To demonstrate a novel approach for the enrichment of specific proteins within EVs.
Methods Used
- Isolation of mEVs from axenic cultures of Mycobacterium smegmatis.
- Designing recombinant mEVs containing mCherry.
- Enrichment of mEVs containing the EsxA protein.
- Verification of the enrichment method through experimental procedures.
Main Results
- Successful enrichment of native mEVs from Mycobacterium smegmatis.
- Development of mCherry-containing recombinant mEVs.
- Verification of the method with EsxA protein-containing mEVs.
- Demonstration of the procedure by a PhD student from the laboratory.
Conclusions
- The method allows for comprehensive enrichment of mycobacterial EVs.
- Recombinant mEVs can be designed for vaccine development.
- This approach enhances the understanding of mycobacterial EV functions.
Frequently Asked Questions
What are mycobacterial extracellular vesicles?
Mycobacterial extracellular vesicles (EVs) are membrane-bound structures released by mycobacteria that play roles in communication and immune response.
How does the enrichment method work?
The method captures all generated mycobacterial EVs, allowing for a comprehensive analysis of their contents.
What is the significance of mCherry in this study?
mCherry serves as a fluorescent reporter to track and analyze the recombinant mycobacterial EVs.
Why is the EsxA protein important?
EsxA is a protein associated with Mycobacterium tuberculosis that may have implications for vaccine development.
Who demonstrated the procedure?
The procedure was demonstrated by Mohd Ilyas, a PhD student from the laboratory.
What are the potential applications of this research?
This research could lead to advancements in vaccine development and a better understanding of mycobacterial biology.
Executive Industry Relevance
Comprehensive enrichment of native and recombinant mycobacterial extracellular vesicles (EVs) enables precise interrogation of vesicle content and function, supporting early-stage target validation and mechanistic de-risking in vaccine and infectious disease research. The ability to engineer and isolate EVs containing specific immunogens or reporters provides a robust platform for evaluating antigen delivery and vesicle-mediated biological effects. This workflow enhances predictive confidence at the discovery-to-preclinical interface for vaccine candidate assessment and portfolio triage.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables systematic analysis of vesicle-associated proteins and immunogens for target validation.
- Supports mechanistic de-risking by clarifying the biological roles of native and engineered EVs.
- Facilitates functional assessment of antigen incorporation and delivery within vesicle systems.
Screening & Assay Development
- Provides standardized enrichment of EVs for reproducible downstream assays.
- Enables quantitative and qualitative assessment of recombinant protein loading in EVs.
- Supports development of scalable, reusable platforms for vesicle-based screening.
Translational & Preclinical Research
- Aligns vesicle content analysis with disease-relevant immunogen delivery for translational studies.
- Enables continuity from discovery through preclinical validation of vesicle-based vaccine candidates.
- Supports risk-adjusted advancement decisions by characterizing vesicle-mediated antigen presentation.
Pipeline & Workflow Integration
This method integrates into the discovery continuum from early hypothesis testing and target validation through assay development and preclinical evaluation of vesicle-based candidates.
- Discovery Biology: Supports hypothesis-driven analysis of vesicle content and function for mechanistic clarity.
- Screening: Delivers reproducible, quantitative EV preparations for assay standardization and compound evaluation.
- Analytics: Provides size, content, and protein incorporation data to compare native and recombinant EVs.
- Translational Research: Enables alignment of vesicle engineering with disease-relevant immunogen delivery.
- Enterprise Reuse: Establishes a reusable workflow for EV enrichment across diverse mycobacterial systems.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in vesicle-based candidate evaluation.
- Operational Value: Standardizes EV enrichment for reproducibility and scalability across R&D teams.
- Strategic Value: Improves go/no-go decisions and capital efficiency by enabling robust target and antigen validation.
- Portfolio Impact: Supports risk-adjusted prioritization of vesicle-based vaccine and therapeutic candidates.
Implementation Considerations
- Requires expertise in bacterial culture, vesicle isolation, and protein engineering.
- Demands access to ultracentrifugation and analytical instrumentation for EV characterization.
- Necessitates cross-team standardization of enrichment and analytical protocols.
- Adaptation may be needed for different mycobacterial species or immunogen constructs.
- Affinity-based enrichment may not capture all EV subtypes due to lack of conserved markers.
Biopharma FAQs
Why does null hypothesis testing matter for EV content analysis?
Null hypothesis testing ensures that observed differences in vesicle content or function are statistically significant, supporting robust target validation and reducing false positives in early discovery.
How does independent variable isolation fit EV enrichment workflows?
Isolating variables such as growth conditions or recombinant constructs allows teams to attribute changes in EV content directly to experimental manipulations, strengthening mechanistic insights.
What do quantitative dependent variable measurements enable in EV studies?
Quantitative measurements of EV size, protein content, and immunogen incorporation enable direct comparison across conditions and inform candidate selection for downstream development.
Why are replication requirements critical for cross-functional EV research?
Replication ensures that EV enrichment and content analysis are reproducible across teams, supporting reliable data sharing and collaborative decision-making in multi-disciplinary R&D environments.
What statistical analysis capabilities are needed before EV workflow implementation?
Teams require statistical tools to assess significance, variability, and reproducibility of EV content and function, enabling data-driven advancement decisions and portfolio risk management.
